TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Support staff for the Elementary Teachers' Federation of Ontario will hit the picket lines at 136 Isabella Street in Toronto this morning. The workers are members of SEIU Local 2 and say ETFO is not treating them with respect and fairness. At issue are wages and paid leave. […]
(NasdaqGM:CNTB), – Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 – – Recruitment ongoing for Phase 2
(NasdaqGM:BCAX), Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 to further characterize ficerafusp alfa's profile in
(NASDAQ:KYTX), Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase
(NASDAQ:CVRX), Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18% Category I
— Study highlights importance of cancer driver biology in translating results from lab to patients — — Findings validate proprietary OncoSLX Platform(TM), a pharmacogenetic approach that captures the full spectrum of drug biology — — Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 lossâ€'ofâ€'function cancers; expect to initiate Phase 1b/2a clinical trial
(NASDAQ:RKDA), DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.(R) (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January
(NASDAQ:GERN), 2026 RYTELO(R) (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Geron Corporation
(NASDAQ:COGT), New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new therapy for second-line GIST in over 20 years Clinical data presentations from all three pivotal trials, PEAK,
(NASDAQ:INAB), Repeat-doses of DeltEx(TM) Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocol Median overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several